Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1987 Jan;23(1):55–63. doi: 10.1111/j.1365-2125.1987.tb03009.x

The effects of naproxen and sulindac on renal function and their interaction with hydrochlorothiazide and piretanide in man.

J J Dixey, F H Noormohamed, A F Lant, D A Brewerton
PMCID: PMC1386140  PMID: 3814463

Abstract

We have studied the effect of a single dose challenge of naproxen (500 mg) and sulindac (200 mg) on renal function in five volunteers, and the effect of a single dose challenge of the thiazide, hydrochlorothiazide (100 mg), and loop diuretic, piretanide (6 mg) on renal function when the diuretics were given alone or when superimposed on chronic therapy of either naproxen or sulindac. None of the nonsteroidal anti-inflammatory drug (NSAID) or diuretic exposures significantly influenced glomerular filtration rate, as measured by creatinine clearance. Over the first 4 h of the study, both naproxen and sulindac reduced fractional excretion of sodium by approximately 50%. Sulindac also caused a significant uricosuria whilst naproxen promoted urate retention. Similar changes were observed over 8 h. Superimposition of either hydrochlorothiazide or piretanide on top of chronic sulindac therapy resulted in a blunting of the natriuresis by approximately 30% compared to when these diuretics were given alone: the action of the diuretics was unchanged by naproxen. Sulindac pretreatment did not alter the urinary excretion of either hydrochlorothiazide or piretanide; naproxen did not alter hydrochlorothiazide excretion. On the basis of these findings, it is concluded that NSAIDs exert direct tubular effects that do not necessarily interfere with the delivery of diuretics to their sites of action within the nephron.

Full text

PDF
55

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berg K. J., Talseth T. Acute renal effects of sulindac and indomethacin in chronic renal failure. Clin Pharmacol Ther. 1985 Apr;37(4):447–452. doi: 10.1038/clpt.1985.69. [DOI] [PubMed] [Google Scholar]
  2. Brater D. C., Anderson S., Baird B., Campbell W. B. Effects of ibuprofen, naproxen, and sulindac on prostaglandins in men. Kidney Int. 1985 Jan;27(1):66–73. doi: 10.1038/ki.1985.11. [DOI] [PubMed] [Google Scholar]
  3. Brater D. C. Drug-drug and drug-disease interactions with nonsteroidal anti-inflammatory drugs. Am J Med. 1986 Jan 17;80(1A):62–77. doi: 10.1016/0002-9343(86)90933-2. [DOI] [PubMed] [Google Scholar]
  4. Carmichael J., Shankel S. W. Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function. Am J Med. 1985 Jun;78(6 Pt 1):992–1000. doi: 10.1016/0002-9343(85)90223-2. [DOI] [PubMed] [Google Scholar]
  5. Chennavasin P., Seiwell R., Brater D. C. Pharmacokinetic-dynamic analysis of the indomethacin-furosemide interaction in man. J Pharmacol Exp Ther. 1980 Oct;215(1):77–81. [PubMed] [Google Scholar]
  6. Data J. L., Rane A., Gerkens J., Wilkinson G. R., Nies A. S., Branch R. A. The influence of indomethacin on the pharmacokinetics, diuretic response and hemodynamics of furosemide in the dog. J Pharmacol Exp Ther. 1978 Aug;206(2):431–438. [PubMed] [Google Scholar]
  7. Duggan D. E., Hare L. E., Ditzler C. A., Lei B. W., Kwan K. C. The disposition of sulindac. Clin Pharmacol Ther. 1977 Mar;21(3):326–335. doi: 10.1002/cpt1977213326. [DOI] [PubMed] [Google Scholar]
  8. Haylor J., Lote C. J. Renal function in conscious rats after indomethacin. Evidence for a tubular action of endogenous prostaglandins. J Physiol. 1980 Jan;298:371–381. doi: 10.1113/jphysiol.1980.sp013087. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kaojarern S., Chennavasin P., Anderson S., Brater D. C. Nephron site of effect of nonsteroidal anti-inflammatory drugs on solute excretion in humans. Am J Physiol. 1983 Feb;244(2):F134–F139. doi: 10.1152/ajprenal.1983.244.2.F134. [DOI] [PubMed] [Google Scholar]
  10. Kirschenbaum M. A., White N., Stein J. H., Ferris T. F. Redistribution of renal cortical blood flow during inhibition of prostaglandin synthesis. Am J Physiol. 1974 Oct;227(4):801–805. doi: 10.1152/ajplegacy.1974.227.4.801. [DOI] [PubMed] [Google Scholar]
  11. Koopmans P. P., Kateman W. G., Tan Y., van Ginneken C. A., Gribnau F. W. Effects of indomethacin and sulindac on hydrochlorothiazide kinetics. Clin Pharmacol Ther. 1985 Jun;37(6):625–628. doi: 10.1038/clpt.1985.100. [DOI] [PubMed] [Google Scholar]
  12. Koopmans P. P., Tan Y., Van Ginneken C. A., Gribnau F. W. High-performance liquid chromatographic determination of hydrochlorothiazide in plasma and urine. J Chromatogr. 1984 May 11;307(2):445–450. doi: 10.1016/s0378-4347(00)84120-1. [DOI] [PubMed] [Google Scholar]
  13. Lant A. Diuretics. Clinical pharmacology and therapeutic use (Part I). Drugs. 1985 Jan;29(1):57–87. doi: 10.2165/00003495-198529010-00003. [DOI] [PubMed] [Google Scholar]
  14. Lonigro A. J., Itskovitz H. D., Crowshaw K., McGiff J. C. Dependency of renal blood flow on prostaglandin synthesis in the dog. Circ Res. 1973 Jun;32(6):712–717. doi: 10.1161/01.res.32.6.712. [DOI] [PubMed] [Google Scholar]
  15. McNabb W. R., Noormohamed F. H., Brooks B. A., Lant A. F. Renal actions of piretanide and three other "loop" diuretics. Clin Pharmacol Ther. 1984 Mar;35(3):328–337. doi: 10.1038/clpt.1984.38. [DOI] [PubMed] [Google Scholar]
  16. Mitnick P. D., Greenberg A., DeOreo P. B., Weiner B. M., Coffman T. M., Walker B. R., Agus Z. S., Goldfarb S. Effects of two nonsteroidal anti-inflammatory drugs, indomethacin and oxaprozin, on the kidney. Clin Pharmacol Ther. 1980 Nov;28(5):680–689. doi: 10.1038/clpt.1980.221. [DOI] [PubMed] [Google Scholar]
  17. Mizgala C. L., Quamme G. A. Renal handling of phosphate. Physiol Rev. 1985 Apr;65(2):431–466. doi: 10.1152/physrev.1985.65.2.431. [DOI] [PubMed] [Google Scholar]
  18. Roberts D. G., Gerber J. G., Barnes J. S., Zerbe G. O., Nies A. S. Sulindac is not renal sparing in man. Clin Pharmacol Ther. 1985 Sep;38(3):258–265. doi: 10.1038/clpt.1985.168. [DOI] [PubMed] [Google Scholar]
  19. Schlondorff D., Ardaillou R. Prostaglandins and other arachidonic acid metabolites in the kidney. Kidney Int. 1986 Jan;29(1):108–119. doi: 10.1038/ki.1986.13. [DOI] [PubMed] [Google Scholar]
  20. Smith D. E., Brater D. C., Lin E. T., Benet L. Z. Attenuation of furosemide's diuretic effect by indomethacin: pharmacokinetic evaluation. J Pharmacokinet Biopharm. 1979 Jun;7(3):265–274. doi: 10.1007/BF01060017. [DOI] [PubMed] [Google Scholar]
  21. Svendsen U. G., Gerstoft J., Hansen T. M., Christensen P., Lorenzen I. The renal excretion of prostaglandins and changes in plasma renin during treatment with either sulindac or naproxen in patients with rheumatoid arthritis and thiazide treated heart failure. J Rheumatol. 1984 Dec;11(6):779–782. [PubMed] [Google Scholar]
  22. Swainson C. P., Griffiths P. Acute and chronic effects of sulindac on renal function in chronic renal disease. Clin Pharmacol Ther. 1985 Mar;37(3):298–300. doi: 10.1038/clpt.1985.43. [DOI] [PubMed] [Google Scholar]
  23. Swainson C. P., Griffiths P., Watson M. L. Chronic effects of oral sulindac on renal haemodynamics and hormones in subjects with chronic renal disease. Clin Sci (Lond) 1986 Mar;70(3):243–247. doi: 10.1042/cs0700243. [DOI] [PubMed] [Google Scholar]
  24. Thompson G. F., Collins J. M. Urinary metabolic profiles for choosing test animals for chronic toxicity studies: application to naproxen. J Pharm Sci. 1973 Jun;62(6):937–941. doi: 10.1002/jps.2600620616. [DOI] [PubMed] [Google Scholar]
  25. Zipser R. D., Henrich W. L. Implications of nonsteroidal anti-inflammatory drug therapy. Am J Med. 1986 Jan 17;80(1A):78–84. doi: 10.1016/0002-9343(86)90934-4. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES